Synexus Site Network — Tempe, Arizona

Synexus Site Network is a clinical research site located in Tempe, Arizona, United States 85282.

Crixeo Clinical Trials Trust Score: 9/100 (FAILING). This profile has not yet been claimed by the site owner.

Synexus Site Network has participated in 1 clinical trials.

Therapeutic areas: Crohn's Disease.

Sponsors: Eli Lilly and Company.

Is this your site?

Is this your site? Claim your profile and control the information sponsors and patients see.

Other research sites in Tempe

Browse all research sites in Arizona · View every site in Tempe

• Tempe St. Luke's Hospital
• Arizona State University Health Services
• Arizona State University: Prevention Research Center
• Prevention Research Center Arizona State University
• Arizona State University
• Autism/Asperger's Research Group at Arizona State University
• Gateway Building, Room 361 & 363, Arizona State University
• Celerion
• Research Site
• Clinical Research Consortium
• Alliance for Multispecialty Research
• GSK Investigational Site

Sponsor Feasibility Report

Trust Score: 9/100. Verification status: Not yet accredited. Patient reviews: 0. Complaints: 0.

Frequently Asked Questions

What is the Trust Score for Synexus Site Network?

Synexus Site Network has a Crixeo Trust Score of 9/100 (FAILING). Trust Scores reflect trial volume, sponsor diversity, patient reviews, address verification, and accreditation status.

How many clinical trials has Synexus Site Network conducted?

Synexus Site Network has 1 clinical trials on record. Their work covers Crohn's Disease.

Is Synexus Site Network accredited by Crixeo Clinical Trials?

Synexus Site Network has not yet obtained Crixeo Accreditation. Site owners can claim their profile and apply for accreditation to improve visibility with sponsors and patients.

Can I submit a review or complaint about Synexus Site Network?

Yes. Patients and trial participants can submit reviews and file complaints directly on this profile page. All submissions are reviewed before publication.